Skip to main content

Advertisement

SpringerLink
Log in

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up

  • Letter to the Editor
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled freedom trial and its extension. J Bone Miner Res 33:190–198

    Article  CAS  Google Scholar 

  2. Reid IR, Horne AM, Mihov B et al (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371–374

    Article  CAS  PubMed  Google Scholar 

  3. Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543

    Article  CAS  PubMed  Google Scholar 

  4. Horne AM, Mihov B, Reid IR (2018) Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif Tissue Int 103:55–61

    Article  CAS  PubMed  Google Scholar 

  5. Reid IR, Horne AM, Mihov B et al (2018) Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379:2407–2416

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Supported by the Health Research Council of New Zealand. The authors are grateful to Greg Gamble for statistical advice.

Author information

Authors and Affiliations

  1. Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand

    Anne M. Horne, Borislav Mihov & Ian R. Reid

  2. Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand

    Ian R. Reid

Authors
  1. Anne M. Horne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Borislav Mihov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian R. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian R. Reid.

Ethics declarations

Conflict of interest

Ian R. Reid has received research grants and honoraria from Amgen, Novartis, Merck, and Lilly. Anne M. Horne and Borislav Mihov have nothing to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horne, A.M., Mihov, B. & Reid, I.R. Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up. Calcif Tissue Int 105, 107–108 (2019). https://doi.org/10.1007/s00223-019-00553-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-019-00553-w

Search

Navigation